Facebook Twitter LinkedIn Google Plus RSS

Salix, Cedars-Sinai go with their gut, strike partnership

By ,
"My philosophy is to treat these microorganisms ... find the right drug to treat the bug." -- Dr. Mark Pimentel. - ()

Bridgewater’s Salix Pharmaceuticals and Cedars-Sinai Medical Center have partnered to develop research for the treatment of gastrointestinal disorders, with a start projected for the third quarter.

Under the agreement, the lab of Dr. Mark Pimentel, executive director of the Medically Associated Science and Technology Program at Cedars-Sinai, will research micro-organisms in the gut, and Salix – a specialty pharmaceutical company whose products are geared toward the prevention and treatment of GI disorders – will have the option to acquire any therapies discovered from the research.

“The gut microbiome represents a great deal of promise and opportunity for disruptive change in gastroenterology,” said Salix President Mark McKenna in a statement.

Salix is a wholly owned subsidiary of Bausch Health Companies Inc.

More From This Industry

Jessica Perry

Jessica Perry

Jessica is the Web Editor for NJBIZ. You can reach her at jperry@njbiz.com.

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy